Paper24978437
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations.
Pistelli M and 12 others. Cancers (Basel), 2014. Cited by 65 papers, by iCite.
Cite this record
ConductScience Library. Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. Papers, record 24978437. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24978437
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04360941 | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer | Background |
Source ClinicalTrials.gov
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21264529 | Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. | Med Oncol | 2012 | https://conductscience.org/library/papers/21264529 | PubMed |
| 2 | 12910513 | Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. | Cancer | 2003 | https://conductscience.org/library/papers/12910513 | PubMed |
| 3 | 10942095 | Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. | Breast Cancer Res Treat | 2000 | https://conductscience.org/library/papers/10942095 | PubMed |
| 4 | 16538529 | Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. | Breast Cancer Res Treat | 2006 | https://conductscience.org/library/papers/16538529 | PubMed |
| 5 | 19638585 | Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. | Cancer Res | 2009 | https://conductscience.org/library/papers/19638585 | PubMed |
| 6 | 23965901 | Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/23965901 | PubMed |
| 7 | 22259247 | Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients. | Breast Cancer (Auckl) | 2012 | https://conductscience.org/library/papers/22259247 | PubMed |
| 8 | 7748811 | Androgens induce divergent proliferative responses in human breast cancer cell lines. | J Steroid Biochem Mol Biol | 1995 | https://conductscience.org/library/papers/7748811 | PubMed |
| 9 | 21325075 | Androgen receptor expression and breast cancer survival in postmenopausal women. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/21325075 | PubMed |
| 10 | 975004 | A demonstration of androgen and estrogen receptors in a human breast cancer using a new protamine sulfate assay. | Cancer | 1976 | https://conductscience.org/library/papers/975004 | PubMed |
| 11 | 9075695 | Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. | Endocrinology | 1997 | https://conductscience.org/library/papers/9075695 | PubMed |
| 12 | 15897907 | Identification of molecular apocrine breast tumours by microarray analysis. | Oncogene | 2005 | https://conductscience.org/library/papers/15897907 | PubMed |
| 13 | 8911118 | The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. | Eur J Cancer | 1996 | https://conductscience.org/library/papers/8911118 | PubMed |
| 14 | 10509795 | Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. | Mol Cell Endocrinol | 1999 | https://conductscience.org/library/papers/10509795 | PubMed |
| 15 | 23031358 | Expression of androgen receptors in triple negative breast carcinomas. | Acta Histochem | 2013 | https://conductscience.org/library/papers/23031358 | PubMed |
| 16 | 7348567 | A prospective evaluation of chemohormonal therapy remission maintenance in advanced breast cancer. | Breast Cancer Res Treat | 1981 | https://conductscience.org/library/papers/7348567 | PubMed |
| 17 | 10819508 | Role of the androgen receptor in human breast cancer. | J Mammary Gland Biol Neoplasia | 1998 | https://conductscience.org/library/papers/10819508 | PubMed |
| 18 | 8100853 | Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. | J Pathol | 1993 | https://conductscience.org/library/papers/8100853 | PubMed |
| 19 | 18507821 | Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. | BMC Cancer | 2008 | https://conductscience.org/library/papers/18507821 | PubMed |
| 20 | 23929266 | Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. | Mod Pathol | 2014 | https://conductscience.org/library/papers/23929266 | PubMed |
Cited by49
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 65 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41948492 | Assessing the prognostic role of androgen receptor expression in non-metastatic triple-negative breast cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/41948492 | PubMed |
| 41723216 | EGFR and AR expression and co-expression in Indian triple-negative breast cancer with patient outcome association. | Sci Rep | 2026 | https://conductscience.org/library/papers/41723216 | PubMed |
| 41444310 | Decoding molecular signatures and identifying therapeutic targets in triple-negative breast cancer subtypes using omics and network analysis. | Sci Rep | 2025 | https://conductscience.org/library/papers/41444310 | PubMed |
| 40846987 | Clinical significance of androgen receptor in unilateral invasive breast cancer in women. | Eur J Med Res | 2025 | https://conductscience.org/library/papers/40846987 | PubMed |
| 40685652 | Androgen receptor expression in triple negative breast cancer: an Algerian population study. | Libyan J Med | 2025 | https://conductscience.org/library/papers/40685652 | PubMed |
| 40448099 | C/EBPβ increases tumor aggressiveness by enhancing KIFC1 expression in androgen receptor negative triple negative breast cancer. | Cell Commun Signal | 2025 | https://conductscience.org/library/papers/40448099 | PubMed |
| 40286049 | Androgen Receptors in Human Breast Cancer and Female Canine Mammary Tumors. | Molecules | 2025 | https://conductscience.org/library/papers/40286049 | PubMed |
| 40150035 | The Diagnostics of Disease Relapse Within Five-Year Follow-Up and the Role of Androgen Receptor Expression in Patients with Early Triple-Negative Breast Cancer. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/40150035 | PubMed |
| 39733399 | Effect of Androgen receptors in Triple-Negative Breast Cancer Given Neoadjuvant Therapy: A Systematic Review and Meta-Analysis. | Asian Pac J Cancer Prev | 2024 | https://conductscience.org/library/papers/39733399 | PubMed |
| 39062096 | Beyond Triple-Negative: High Prevalence of Quadruple-Negative Breast Cancer in African Americans. | Biomedicines | 2024 | https://conductscience.org/library/papers/39062096 | PubMed |
| 39020535 | Triple-negative breast cancer: from classical clinicopathological features to androgen receptor profile. | Rom J Morphol Embryol | 2024 | https://conductscience.org/library/papers/39020535 | PubMed |
| 38790919 | Frequency of Androgen Receptor Positivity in Tumors: A Study Evaluating More Than 18,000 Tumors. | Biomedicines | 2024 | https://conductscience.org/library/papers/38790919 | PubMed |
| 38741650 | Incidence and Prognostic Significance of Androgen Receptors (AR) in Indian Triple-Negative Breast Cancer (TNBC). | Indian J Surg Oncol | 2024 | https://conductscience.org/library/papers/38741650 | PubMed |
| 38555429 | The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification. | Cancer Cell Int | 2024 | https://conductscience.org/library/papers/38555429 | PubMed |
| 37794999 | Does a 40% Cut-off Point for Ki-67 Expression Have a Role in Identifying the Development of Distant Metastasis Within 2 Years in Locally Advanced Triple Negative Breast Cancer Patients? | Eur J Breast Health | 2023 | https://conductscience.org/library/papers/37794999 | PubMed |
| 37553450 | Subcellular expression pattern and clinical significance of CBX2 and CBX7 in breast cancer subtypes. | Med Mol Morphol | 2024 | https://conductscience.org/library/papers/37553450 | PubMed |
| 37435469 | SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients. | Endocr Oncol | 2022 | https://conductscience.org/library/papers/37435469 | PubMed |
| 36232774 | AR Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of ESR1 Expression Status. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36232774 | PubMed |
| 36006309 | Hormonal Homologies between Canine Mammary Cancer and Human Breast Cancer in a Series of Cases. | Vet Sci | 2022 | https://conductscience.org/library/papers/36006309 | PubMed |
| 35203574 | Translational Implications of Dysregulated Pathways and microRNA Regulation in Quadruple-Negative Breast Cancer. | Biomedicines | 2022 | https://conductscience.org/library/papers/35203574 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALDH1A1 | 216 | PubTator's text mining | https://conductscience.org/library/genes/216 | NCBI Gene |
| AR | 367 | PubTator's text mining | https://conductscience.org/library/genes/367 | NCBI Gene |
| CDH1 | 999 | PubTator's text mining | https://conductscience.org/library/genes/999 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
| RIEG2 | 6012 | PubTator's text mining | https://conductscience.org/library/genes/6012 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24978437
GET https://conductscience.org/api/papers/v1/24978437/references?page=2